*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p>This fixed-dose combination integrates Dolutegravir, Lamivudine, and Tenofovir Alafenamide (TAF) for HIV-1 management. It represents a potent integrase strand transfer inhibitor regimen. <strong>Molecular Formula</strong>: C<sub>29</sub>H<sub>24</sub>N<sub>8</sub>O<sub>6</sub> (Dolutegravir) + C<sub>10</sub>H<sub>15</sub>N<sub>3</sub>O<sub>3</sub>S (Lamivudine) + C<sub>18</sub>H<sub>28</sub>N<sub>4</sub>O<sub>7</sub>P (TAF). Specific CAS numbers vary by API component.</p>
<h3>Application</h3>
<ul>
<li>Treatment-naïve adults initiating antiretroviral therapy.</li>
<li>Switching regimens from established viral suppression protocols.</li>
<li>First-line prevention of HIV transmission in high-risk populations.</li>
</ul>
<h3>Precautions</h3>
<p>Contraindicated with strong inducers like rifampin. Monitor renal function due to TAF accumulation risks. Store at controlled room temperature below 25°C away from moisture.</p>